Kyrgyz State Medical Academy

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

Pulmonary Function Testing
Academy Board Prep PCCM
Respiratory Function Tests RFTs
Physiology Lab Spirometry
Respiratory Volumes Used to assess a person’s respiratory status
Pulmonary Volumes and Capacities—Spirometry A simple method for studying pulmonary ventilation is to record the volume movement of air into and out of.
Copyright © 2013, 2009, 2003, 1999, 1995, 1990, 1982, 1977, 1973, 1969 by Mosby, an imprint of Elsevier Inc. Chapter 19 Pulmonary Function Testing.
2005 PPC Lectures Series: Pulmonary Function Tests Kimberly Otsuka, M.D. Pediatric Pulmonary Fellow September 19, 2005.
RESPIRATION Dr. Zainab H.H Dept. of Physiology Lec.5,6.
Respiratory function tests
Pulmonary function test By Maisa Mansour, MD. PFT PTF is one of the most important and most frequently utilized investigations in our field. Why do.
Respiratory Function Test Department of internal medicine Chen Yu.
Respiratory Function, Breathing, Respiration
Respiratory Fitness Ashlea Lockett, Nicky Gilchrist & Jenna Cruickshank.
Respiratory Function Tests Fiona Gilmour SHO 03/06/04.
PULMONARY FUNCTION TESTS
PULMONARY FUNCTION MEASUREMENTS MODULE D. Objectives At the completion of this module you will: List the four lung volumes including the following information:
Respiratory Function Test Department of internal medicine Chen Yu.
Respiratory Function, Breathing, Respiration BI 233 Exercise 40.
Lung Function Tests Normal and abnormal Prof. J. Hanacek, MD, PhD.
Normal and abnormal Prof. J. Hanacek, MD, PhD
1 Pulmonary Function Tests J.B. Handler, M.D. Physician Assistant Program University of New England.
Pulmonary Function David Zanghi M.S., MBA, ATC/L, CSCS.
Pulmonary Function Testing (PFT)
Pulmonary Function Measurements
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.
These are measured with a spirometer This is estimated, based on
Pulmonary Function Tests Cori Daines, M.D. October 6, 2009.
Spirometry A. H. Mehrparvar, MD Occupational Medicine department Yazd University of Medical Sciences.
Core Pulmonary Concepts. Lung volumes and capacities.
Pulmonary Function Measurements Chapter 5. VOLUMES AND CAPACITIES TLC RV Vt VC IC IRV FRC ERV.
Pulmonary Function Tests Eloise Harman. Symptoms of Lung Disease Cough, productive or unproductive Increased sensitivity to odors and irritants Pleuritic.
An Overview of Pulmonary Function Tests Norah Khathlan M.D. Consultant Pediatric Intensivist 10/2007.
23-Jan-16lung functions1 Lung Function Tests Ventilatory Functions Gas Exchange.
Pulmonary Function Tests (PFTs)
Respiratory Function Tests RFTs. Review Of Anatomy & physiology Lungs comprised of  Airways  Alveoli.
SPIROMETRY (Pulmonary Function Testing)
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.
Clinical Application of Pulmonary Function Tests Sevda Özdoğan MD, Prof. Chest Diseases.
The Spirometry 1 Dr Mazen Qusaibaty MD, DIS / Head Pulmonary and Internist Department Ibnalnafisse Hospital Ministry of Syrian health –
PULMONARY FUNCTION TEST(PFT)
Pulmonary function tests & Lung volumes & capacities Prof. Omer Abdel Aziz.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary function in primary pulmonary hypertension.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Obstructive Lung Disease and Low Lung Function in.
Pulmonary Function Tests Pulmonary Function Tests Marcus A. Nesbeth PA-C June 19, 2009.
Tutorial – Lung Function Testing. Lung Function in Obstructive/Restrictive Disease VC VC VC TLC VT RV VOLUME (litres) NormalCOPD VT ERV RV
An Approach For Spirometry and DLCO Interpretation
Lung Function Test Physiology Lab-3 March, 2017.
PFT of the Day!.
RESPIRATORY SYSTEM (LUNG VOLUMES & CAPACITIES)
RESPIRATORY VENTILATION
These are measured with a spirometer This is estimated, based on
Copyright © 2015 by the American Osteopathic Association.
Pulmonary Function Tests
Lung volume and lung capacity By DR AGBARAOLORUNPO F
The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD
Respiratory Volumes Used to assess a person’s respiratory status
PFT.
Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation  Nicholas J. Gross, MD,
Lung Volumes 17-Apr-19 Lung Volumes.
Changes in operating lung volumes are shown as ventilation increases with exercise in a) age-matched normal subjects (n = 25) and b) chronic obstructive.
تست عملکرد ریوی SPIROMETERY.
Spirometry A. H. Mehrparvar, MD Occupational Medicine department
Respiratory Function Test
RESPIRATORY VENTILATION
Exertional dyspnoea intensity is shown relative to a) work rate and b) diaphragm electromyography relative to maximum (EMGdi/EMGdi,max) during incremental.
Pressure (P)–volume (V) relationships of the total respiratory system a) in normal and b) in chronic obstructive pulmonary disease (COPD). Pressure (P)–volume.
E. Rand Sutherland, MD, MPH  Journal of Allergy and Clinical Immunology 
A: Changes in percent of predicted following bronchodilator for spirometric and lung volumes variables. A: Changes in percent of predicted following bronchodilator.
Presentation transcript:

Kyrgyz State Medical Academy Department of Internal Diseases Effect of 6 month therapy with "Seretid" in COPD patients

One of the aims in treatment of COPD is long time bronchodilator therapy which causes decrease in intensity of disease symptoms, lower down the frequency and severity of disease, tolerance to physical activity and improvement in life quality.. In last some decades many facts were collected according to which it is proved that in broncholytic therapy, corticosteroids can be added to treat COPD. To study the effect of 6 month therapy with "Seretid" were observed 20 patients suffering from chronic obstructive pulmonary disease (COPD), registered in center of family medicines № 7 Bishkek. During 6 months, patients took “Seretid” in dose of 500 micrograms 2 times a day, using inhalers. The effect of treatment was estimated by decrease in dyspnoea, cough and sputum production, tolerance to physical activity. Except this after 6 months seretid treatment, observed decrease in cough syndrome, significantly increasing rates OFV1, and the distance in 6 minutes walk test. The purpose of our study was to examine the effect of 6 - month therapy with "Seretid" in chronic obstructive pulmonary disease patients.

Generally lung function values in obstructive disease Lung function test Result as predicted for age, height, sex, weight, or race Forced vital capacity (FVC) Normal or lower than predicted value Forced expiratory volume (FEV1) Lower FEV1 divided by FVC Forced expiratory flow 25% to 75% Peak expiratory flow (PEF) Maximum voluntary ventilation (MVV) Slow vital capacity (SVC) Normal or lower Total lung capacity (TLC) (VT) Normal or higher Functional residual capacity (FRC) Higher Residual volume (RV) Expiratory reserve volume (ERV) RV divided by TLC ratio

Material and Methods We examined 20 patients with COPD medium sever and sever who were registered in CFM no. 7 Bishkek. The average age of patients was 55 ± 7,0 years. During 6 months, patients took seretid in a dose of 500 micrograms 2 times a day, using inhalers. Before and after treatment, all patients were examined “forced expiratory flow” by "M aster-Lab" (Germany). Tolerance to physical load was estimated by “six minutes walk test” distance measured in meters, dyspnoea according to scale Borge and saturation with help of Spiro meter. Cough and sputum were estimated by scale 4-points: 0-no symptoms; 1-mild cough, mild sputum production; 2-moderate cough; 3-moderate sputum production; 4-marked cough, big sputum production. Improvement in life quality was measured according to SGRQ, according to that estimated domain “symptoms”, “activeness”, “action” and “general life quality”.

Lung volume calculate Lung Capacity test

Results and Discussion At the end of third month, treatment with Seretid (table 1), observed improvement in cough (from 2.03 to 1.23), sputum production (from 0.85, p< 0.05) and dysponea (from 1.48 to 0.93, p<0.01).

The dynamics of symptoms after 6 months, treatment of COPD patients with Seretid (In points) Before Treatment After 3 months After 6 months Cough 2,03 ± 0,14 1,23 ± 0,17* 1,05 ± 0,15* Sputum 1,25 ± 0,14 0,85 ± 0,11* 0,78 ± 0,08* Dyspnoea 1,48 ± 0,22 0,93 ± 0,17* 0,80 ± 0,17*

After three months treatment with Seretid there was decrease in cough syndrome (from 2.03 to 1.05 points, p<0.001) persisted throughout treatment period, except this at the end of 6 month seretid therapy sputum was absent totally (from 1.25 to 0.78), decrease in dyspnoea period (from 0.48 to 0.80 points, p< 0.01), FEV1was increased and FEV1%(from 2.07 to 2.54 points and from 66.4 to 61.13 points, p<0.01). With improvement in FEV1 and FEV1 %, there was also improvement in physical load. In 6 minutes walk test (table 2) improvement was noted (at end of treatment distance was 40.1 m, p< 0.05) with decrease in dyspnoea according to scale of Borge from 5.7 to 3.9 points.

Dynamics showing Forced expiratory volume and tolerance to physical load in COPD patients in 6 month Seretid therapy process No. Activities Before treatment (n -20) After 3 months (n - 20) After 6 months 1. lung vital capacity (l) 3,35 ± 0,20 3,51 ± 0,24 3,70 ± 0,20 2. lung vital capacity 88,22 ± 4,81 88,56 ± 4,26 96,06 ± 4,04 3. FEV 2,07 ± 0,14 2,30 ± 0,19 2,54 ± 0,15* 4. Forced expiratory volume (% proper) 66,44 ± 4,16 72,08 ± 5,14 81,13 ± 4,62* 5. FEV1/lung vital capacity 61,01 ± 2,64 69,56 ± 3,15 68,9 ± 2,92 6. maximum voluntary ventilation 3,21 ± 0,19 3,80 ± 0,37 3,70 ± 0,22 7. FEV1/maximal expiratory flow volume 57,92 ± 5,14 68,50 ± 1,51 69,40 ± 2,61 8 6 minutes walk test (m) 336,4 ± 11,0 357,4 ± 13,7 376,4 ± 13,6* 9 Dyspnoea during walk test 5,72 ± 0,50 4,42 ± 0,37 3,90 ± 0,32*

Activities Initial After 6 months The results, improvement in life quality, estimated with help of SGRQ before and after 6 month treatment with Seretid are shown in table no. 3 Activities Initial After 6 months Symptoms 78.1 57.0* Activeness 52.1 39.4* Ascendancy 45.6 35.6* Total points 53.0 40.3*

Conclusion Prolonged “Seretid” therapy causes decrease in cough syndrome and improvement in bronchial passage in COPD patients. After 6 month of Seretid therapy, tolerance to physical load increased which was observed in 6 minutes walk test. Seretid caused improvement in life quality according to all scales of SGRQ

Thank you for Attention